StockNews.com initiated coverage on shares of IRIDEX (NASDAQ:IRIX – Free Report) in a research note issued to investors on Thursday morning. The brokerage issued a hold rating on the medical equipment provider’s stock.
IRIDEX Trading Down 1.3 %
IRIDEX stock opened at $1.52 on Thursday. The business’s 50 day simple moving average is $1.81 and its 200 day simple moving average is $2.18. IRIDEX has a 12 month low of $1.45 and a 12 month high of $3.65. The company has a market cap of $25.10 million, a price-to-earnings ratio of -2.30 and a beta of 0.78.
IRIDEX (NASDAQ:IRIX – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The medical equipment provider reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04). IRIDEX had a negative return on equity of 134.37% and a negative net margin of 21.84%. The firm had revenue of $12.63 million for the quarter, compared to the consensus estimate of $12.80 million. During the same quarter in the previous year, the company posted ($0.17) EPS.
Institutional Inflows and Outflows
About IRIDEX
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
Featured Stories
- Five stocks we like better than IRIDEX
- How to Invest in Biotech Stocks
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- How to Evaluate a Stock Before Buying
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is the Hang Seng index?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.